[HTML][HTML] The prostate cancer landscape in Europe: Current challenges, future opportunities
Prostate cancer (PCa) is the most common non-cutaneous cancer in men in Europe and is
predicted to exhibit declining mortality in the European Union (EU) due to various recent …
predicted to exhibit declining mortality in the European Union (EU) due to various recent …
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
Introduction 177Lu-vipivotide tetraxetan is a radiopharmaceutical that selectively targets
prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate …
prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate …
General concepts in theranostics
The term “theranostics” was conceived in 2002 1 with the acronym made by the fusion of the
words “therapy” and “diagnostics.” Simplistically, the terminology describes the combined …
words “therapy” and “diagnostics.” Simplistically, the terminology describes the combined …
[HTML][HTML] Radiometal-theranostics: the first 20 years
F Roesch, M Martin - Journal of Radioanalytical and Nuclear Chemistry, 2023 - Springer
This review describes the basic principles of radiometal-theranostics and its dawn based on
the development of the positron-emitting 86Y and 86Y-labeled radiopharmaceuticals to …
the development of the positron-emitting 86Y and 86Y-labeled radiopharmaceuticals to …
[HTML][HTML] PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
In 1853, the perception of prostate cancer (PCa) as a rare ailment prevailed, was described
by the eminent Londoner surgeon John Adams. Rapidly forward to 2018, the landscape …
by the eminent Londoner surgeon John Adams. Rapidly forward to 2018, the landscape …
[HTML][HTML] Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to …
L Flegar, SG Thoduka, D Librizzi, M Luster… - European Journal of …, 2023 - Springer
Purpose This study is to investigate the adoption and current trends of Lutetium-177 PSMA
RLT for mCRPC in Germany. Methods We analyzed data from the reimbursement. INFO tool …
RLT for mCRPC in Germany. Methods We analyzed data from the reimbursement. INFO tool …
[HTML][HTML] Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
Y Yan, H Zhuo, T Li, J Zhang, M Tan, Y Chen - Frontiers in Oncology, 2024 - frontiersin.org
Prostate cancer (PCa), a leading global health concern, profoundly impacts millions of men
worldwide. Progressing through two stages, it initially develops within the prostate and …
worldwide. Progressing through two stages, it initially develops within the prostate and …
Molecular Imaging for Radiolabeling a PSMA-Targeted Long Circulating Peptide as a Theranostic Agent in Mice Bearing a Human Prostate Tumor
MH Li, SN Lo, MW Chen, WL Lo, YR Huang… - Journal of Medical and …, 2021 - Springer
Abstract Purpose 177 Lu-PSMA-617 is a promising radiotheranostic agent for metastatic
castration-resistant prostate cancer (mCRPC) patients that is composed of prostate-specific …
castration-resistant prostate cancer (mCRPC) patients that is composed of prostate-specific …